Description
Product details
Patented technology Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
How are conjugated primary antibodies validated? This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling. For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on recombinant antibodies.
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
FXR1 is involved in the post-transcriptional regulation of gene expression important for normal cell function and development. It forms a complex with FMRP playing an important role in the transport and translation of specific subsets of mRNAs in neurons. This interaction suggests it contributes significantly to the synaptic plasticity mechanisms influencing learning and memory. Moreover FXR1 also seems to have functions in cell proliferation and muscle differentiation.
Pathways
FXR1 participates in key regulatory pathways of protein synthesis and neuronal communication. It is significant in the mTOR signaling pathway where it potentially interacts with other proteins like FXR2 and FMR1 to modulate translational control. FXR1's involvement in this pathway suggests a role in cellular growth and neuron-specific processes affecting how cells respond to various growth signals by altering protein synthesis rates.